Skip to main content

Table 1 Summary of preclinical, translational, and clinical evidence of the DRibbles vaccine

From: Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

In the Lab

Bench to Bedside

In the Clinic

• DRibbles vaccine comprises autophagosome-packaged cellular proteins, short-lived proteins and ribosomal proteins that may be missed by endogenous immunity

• The DPV-001 DRibbles contains over 2,000 proteins, of which 25 are known tumor-associated antigens

• Dribbles vaccine + docetaxel was well tolerated in a phase I NSCLC trial

• DRibbles delays growth in both “autologous” and “allogeneic” pre-preclinical models

• The DPV-001 cell lines contain thousands of mutations and polymorphisms that could function as altered-peptide ligands

• A Phase II trial comparing DRibbles + either GM-CSF or Imiquimod in stage IIIA/B NSCLC is ongoing

• DRibbles contains innate immunity mediators (DAMPs) and surface ligands for CLEC9a, which facilitate uptake by APCs for cross-presentation

• Each lung adenocarcinoma sequence from the TCGA database shares at least one mutation with the polymorphisms found in DPV-001

• A Phase I trial of DRibbles + imiquimod + low-dose cyclophosphamide is ongoing

 

• DPV-001 contains common oncogene mutants such as KRAS G12C

• DRibbles induced increased antibody reactivity in the first 2 patients treated on a phase II trial